Randomized trial of low-dose aspirin for PI3K-altered localized colorectal cancer

Aspirin reduces the incidence of colorectal adenoma and colorectal cancer among high-risk persons. The ALASCCA study in Sweden, Denmark, Finland, and Norway randomized patients with PI3K-altered localized colorectal cancer within 12 weeks of surgery 1:1 to 160 mg of aspirin or matched placebo once daily for 3 years. Aspirin led to a significantly lower incidence of colorectal cancer recurrence. Severe adverse events occurred in 16.8% of aspirin recipients and 11.6% of placebo recipients (quick take video summary).